Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05264714 · ClinicalTrials.gov registry record · Phase 2
Cluster Headache Treatment With Rimegepant
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT05264714: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT05264714 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05264714, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this research is to explore the efficacy of rimegepant as a preventative therapy for cluster headache.
Primary Outcome
Total number of cluster headache attacks experienced in one week
Interventions
- DRUG Rimegepant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-09-07 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
What the finished NCT05264714 record still lists
NCT05264714 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which Rimegepant is the first listed.
NCT05264714 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05264714 about?
NCT05264714 is a clinical study titled "Cluster Headache Treatment With Rimegepant". The purpose of this research is to explore the efficacy of rimegepant as a preventative therapy for cluster headache.
What is the current status of trial NCT05264714?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2022-09-07. Estimated completion is 2025-12-31.
What interventions are being tested in trial NCT05264714?
The interventions under investigation include: Rimegepant (DRUG).
Who is sponsoring clinical trial NCT05264714?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05264714's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI